Published in Int Psychogeriatr on January 01, 1997
High consistency of regional cortical thinning in aging across multiple samples. Cereb Cortex (2009) 2.88
Consistent neuroanatomical age-related volume differences across multiple samples. Neurobiol Aging (2009) 2.08
Increased sensitivity to effects of normal aging and Alzheimer's disease on cortical thickness by adjustment for local variability in gray/white contrast: a multi-sample MRI study. Neuroimage (2009) 1.42
Delirium superimposed on dementia is associated with prolonged length of stay and poor outcomes in hospitalized older adults. J Hosp Med (2013) 1.39
Accelerating cortical thinning: unique to dementia or universal in aging? Cereb Cortex (2012) 1.20
Whole brain quantitative T2 MRI across multiple scanners with dual echo FSE: applications to AD, MCI, and normal aging. Neuroimage (2010) 0.89
Correlates of Subjective and Mild Cognitive Impairment: Depressive Symptoms and CSF Biomarkers. Dement Geriatr Cogn Dis Extra (2013) 0.86
High degree of heterogeneity in Alzheimer's disease progression patterns. PLoS Comput Biol (2011) 0.85
The Gothenburg MCI study: Design and distribution of Alzheimer's disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up. J Cereb Blood Flow Metab (2016) 0.81
MEG spectral analysis in subtypes of mild cognitive impairment. Age (Dordr) (2014) 0.81
Entropy and Complexity Analyses in Alzheimer's Disease: An MEG Study. Open Biomed Eng J (2010) 0.81
White matter integrity and cognition in Parkinson's disease: a cross-sectional study. BMJ Open (2014) 0.80
[Users of regional dementia care networks in Germany : First results of the evaluation study DemNet-D]. Z Gerontol Geriatr (2016) 0.79
Guiding functional connectivity estimation by structural connectivity in MEG: an application to discrimination of conditions of mild cognitive impairment. Neuroimage (2014) 0.79
Discomfort and agitation in older adults with dementia. BMC Geriatr (2007) 0.79
The Combination of Dysexecutive and Amnestic Deficits Strongly Predicts Conversion to Dementia in Young Mild Cognitive Impairment Patients: A Report from the Gothenburg-Oslo MCI Study. Dement Geriatr Cogn Dis Extra (2014) 0.78
Synchronization during an internally directed cognitive state in healthy aging and mild cognitive impairment: a MEG study. Age (Dordr) (2014) 0.78
Facilitating ADLs by caregivers of persons with dementia: the C3P model. Occup Ther Health Care (2014) 0.77
White matter hyperintensity microstructure in amyloid dysmetabolism. J Cereb Blood Flow Metab (2016) 0.77
Amyloid Dysmetabolism Relates to Reduced Glucose Uptake in White Matter Hyperintensities. Front Neurol (2016) 0.75
Apraxia for differentiating Alzheimer's disease from subcortical vascular dementia and mild cognitive impairment. Neuropsychiatr Dis Treat (2013) 0.75
Subjective Cognitive Impairment Is a Predominantly Benign Condition in Memory Clinic Patients Followed for 6 Years: The Gothenburg-Oslo MCI Study. Dement Geriatr Cogn Dis Extra (2017) 0.75
MEG Beamformer-Based Reconstructions of Functional Networks in Mild Cognitive Impairment. Front Aging Neurosci (2017) 0.75
Validation of the multimodal assessment of capacities in severe dementia: a novel cognitive and functional scale for use in severe dementia. J Neurol (2015) 0.75
The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry (1982) 10.83
Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A (2001) 3.86
Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 3.77
Functional assessment staging (FAST). Psychopharmacol Bull (1988) 3.42
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging (2005) 3.00
Mild cognitive impairment in the elderly: predictors of dementia. Neurology (1991) 2.83
Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neurobiol Aging (1997) 2.68
Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry (1987) 2.65
Global Deterioration Scale (GDS). Psychopharmacol Bull (1988) 2.14
Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol (1999) 1.93
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease. Neurology (2004) 1.86
MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med (2004) 1.77
Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. J Neuropathol Exp Neurol (1997) 1.67
Dementia: a systematic approach to identifying reversible causes. Geriatrics (1986) 1.55
Brief Cognitive Rating Scale (BCRS). Psychopharmacol Bull (1988) 1.55
Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int Psychogeriatr (1992) 1.54
The effects of mood changes and antidepressants on the cognitive capacity of elderly depressed patients. Int Psychogeriatr (1989) 1.50
Patterns of motor impairement in normal aging, mild cognitive decline, and early Alzheimer's disease. J Gerontol B Psychol Sci Soc Sci (1997) 1.39
Medical and economic benefit of a comprehensive infection control program that includes routine determination of microbial clonality. Am J Clin Pathol (1999) 1.39
Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. Arch Neurol (1992) 1.33
Neurofibrillary pathology--correlation with hippocampal formation atrophy in Alzheimer disease. Neurobiol Aging (1997) 1.30
Equilibrium and limb coordination in mild cognitive impairment and mild Alzheimer's disease. J Am Geriatr Soc (1999) 1.24
Effects of naloxone in senile dementia: a double-blind trial. N Engl J Med (1983) 1.23
Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer's disease. J Cereb Blood Flow Metab (1983) 1.13
Positron emission tomographic studies of aging and Alzheimer disease. AJNR Am J Neuroradiol (1983) 1.13
Neuronal and volume loss in CA1 of the hippocampal formation uniquely predicts duration and severity of Alzheimer disease. Brain Res (1998) 1.12
In vitro antibacterial activity of trimethoprim alone and combined with sulfonamides. Antimicrob Agents Chemother (Bethesda) (1966) 1.12
Side effects associated with lithium therapy. Arch Gen Psychiatry (1979) 1.11
An overview of current concepts of Alzheimer's disease. Am J Psychiatry (1982) 1.11
Cerebellar atrophy in Alzheimer's disease-clinicopathological correlations. Brain Res (1999) 1.09
Prediction of longitudinal cognitive decline in normal elderly with subjective complaints using electrophysiological imaging. Neurobiol Aging (2005) 1.06
Alzheimer's disease: longitudinal CT studies of ventricular change. AJR Am J Roentgenol (1989) 1.05
A two-year longitudinal study of cognitive function in normal aging and Alzheimer's disease. J Geriatr Psychiatry Neurol (1993) 1.05
The neglected half of Alzheimer disease: cognitive and functional concomitants of severe dementia. J Am Geriatr Soc (1994) 1.02
Positron emission tomography and computed tomography assessments of the aging human brain. J Comput Assist Tomogr (1984) 1.00
Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's disease. Dement Geriatr Cogn Disord (2007) 1.00
Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD. Curr Alzheimer Res (2010) 0.98
Clinical evaluation of global change in Alzheimer's disease: identifying consensus. J Geriatr Psychiatry Neurol (1996) 0.98
A longitudinal study of cognitive function in elderly persons with subjective memory complaints. J Am Geriatr Soc (1993) 0.98
Duration of neurofibrillary changes in the hippocampal pyramidal neurons. Brain Res (1998) 0.97
Atrophy of hippocampal formation subdivisions correlates with stage and duration of Alzheimer disease. Dementia (1995) 0.97
The neurologic syndrome of severe Alzheimer's disease. Relationship to functional decline. Arch Neurol (1993) 0.96
The Empirical Behavioral Pathology in Alzheimer's Disease (E-BEHAVE-AD) Rating Scale. Int Psychogeriatr (1996) 0.95
Dexamethasone suppression in dementia, depression, and normal aging. Am J Psychiatry (1986) 0.94
Contractures and loss of function in patients with Alzheimer's disease. J Am Geriatr Soc (1995) 0.94
Diagnosis and assessment of the older patient. Hosp Community Psychiatry (1982) 0.94
Computed tomography evaluations of brain-behavior relationships in senile dementia of the Alzheimer's type. Neurobiol Aging (1980) 0.94
Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease? Parkinsonism Relat Disord (2005) 0.94
Catatonia associated with disulfiram therapy. J Nerv Ment Dis (1978) 0.91
Quantitative EEG correlates of cognitive deterioration in the elderly. Neurobiol Aging (1994) 0.90
Cephaloridine. Studies of therapeutic activity and untoward effects. Arch Intern Med (1968) 0.90
Vascular fibrosis and calcification in the hippocampus in aging, Alzheimer disease, and Down syndrome. Acta Neuropathol (2001) 0.90
An overview of pharmacologic treatment of cognitive decline in the aged. Am J Psychiatry (1981) 0.90
Longitudinal course of normal aging and progressive dementia of the Alzheimer's type: a prospective study of 106 subjects over a 3.6 year mean interval. Prog Neuropsychopharmacol Biol Psychiatry (1986) 0.89
Correlations between computerised tomographic changes and behavioural deficits in senile dementia. Lancet (1979) 0.89
Reliability of routine clinical instruments for the assessment of Alzheimer's disease administered by telephone. J Geriatr Psychiatry Neurol (1998) 0.88
Addition of a frequency-weighted score to the Behavioral Pathology in Alzheimer's Disease Rating Scale: the BEHAVE-AD-FW: methodology and reliability. Eur Psychiatry (2001) 0.88
Neuromotor changes in Alzheimer's disease: implications for patient care. J Geriatr Psychiatry Neurol (1997) 0.86
NYU computerized test battery for assessing cognition in aging and dementia. Psychopharmacol Bull (1988) 0.86
Motor/psychomotor dysfunction in normal aging, mild cognitive decline, and early Alzheimer's disease: diagnostic and differential diagnostic features. Int Psychogeriatr (1997) 0.86
The wills of older people: risk factors for undue influence. Int Psychogeriatr (2008) 0.85
Measuring cognition in advanced Alzheimer's disease for clinical trials. J Neural Transm Suppl (2002) 0.84
An ordinal functional assessment tool for Alzheimer's-type dementia. Hosp Community Psychiatry (1985) 0.83
18F-2-deoxy-2-fluoro-D-glucose as a tracer in the positron emission tomographic study of senile dementia. Am J Psychiatry (1982) 0.82
Management of behavior disturbance in Alzheimer disease: current knowledge and future directions. Alzheimer Dis Assoc Disord (1992) 0.82
Regional correlation of PET and CT in senile dementia of the Alzheimer type. AJNR Am J Neuroradiol (1983) 0.81
Remediable behavioral symptomatology in Alzheimer's disease. Hosp Community Psychiatry (1986) 0.81
Positron emission tomography in the study of aging and senile dementia. Neurobiol Aging (1980) 0.81
Informant-rated activities-of-daily-living (ADL) assessments: results of a study of 141 items in the U.S.A., Germany, Russia, and Greece from the International ADL Scale Development Project. Alzheimer Dis Assoc Disord (1997) 0.81
Cognition-independent neurologic symptoms in normal aging and probable Alzheimer's disease. Arch Neurol (1991) 0.80
Staging methods for the assessment of dementia: Perspectives. J Clin Psychiatry (1996) 0.79
Abnormal temporal lobe response in Alzheimer's disease during cognitive processing as measured by 11C-2-deoxy-D-glucose and PET. J Cereb Blood Flow Metab (1987) 0.79
Sister chromatid exchanges and cell cycle kinetics in Alzheimer's disease. Biol Psychiatry (1984) 0.79
First results on the effects of MAO inhibition on cognitive functioning in elderly depressed patients. Arch Gerontol Geriatr (1983) 0.79
Novel pharmacologic approaches to the treatment of senile dementia of the Alzheimer's type (SDAT). Psychopharmacol Bull (1983) 0.78
A clinical rating scale for symptoms of psychosis in Alzheimer's disease. Psychopharmacol Bull (1985) 0.78
Institutionalization of Alzheimer's disease patients: reducing precipitating factors through family counseling. Home Health Care Serv Q (1987) 0.78
Temporal order of cognitive and functional loss in a nursing home population. J Am Geriatr Soc (1995) 0.78
Fibrillar amyloid-beta affects neurofibrillary changes but only in neurons already involved in neurofibrillary degeneration. Acta Neuropathol (2001) 0.77
Psychostimulants and neuropeptides in geropsychiatry [proceedings]. Psychopharmacol Bull (1980) 0.77
Periventricular lucencies in the CT scans of aged and demented patients. Biol Psychiatry (1986) 0.77
Utility of developmental reflexes in the differential diagnosis and prognosis of incontinence in Alzheimer's disease. J Geriatr Psychiatry Neurol (1997) 0.77
Long-term choline treatment of memory-impaired elderly patients. Science (1979) 0.77
Clinical response to choline plus piracetam in senile dementia: relation to red-cell choline level. N Engl J Med (1981) 0.77
Equivalent spatial-rotation deficits in normal aging and Alzheimer's disease. J Clin Exp Neuropsychol (1988) 0.77
Management of fluoroquinolone resistance in Pseudomonas aeruginosa--outcome of monitored use in a referral hospital. Int J Antimicrob Agents (1998) 0.76
Alzheimer's disease. Stages of cognitive decline. Am J Nurs (1984) 0.76
Neurologic markers of the progression of Alzheimer's disease. Int Psychogeriatr (1997) 0.75
Positron emission tomography in dementia. Adv Neurol (1983) 0.75
Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type. J Am Geriatr Soc (1992) 0.75
Pharmacotherapy of senile dementia. Proc Annu Meet Am Psychopathol Assoc (1980) 0.75
Pharmacologic treatment of aggressive syndromes. Curr Psychiatr Ther (1978) 0.75
[Methodological problems in geriatric psychopharmacology]. Presse Med (1983) 0.75
Application of Piagetian measures of cognition in severe Alzheimer's disease. Psychiatr J Univ Ott (1990) 0.75
Behavioral symptoms in dementia: community-based research. Int Psychogeriatr (1996) 0.75
Relationship between cognition and mood in geriatric depression. Psychopharmacol Bull (1982) 0.75
Mucormycosis after open fracture injury. South Med J (1985) 0.75
Beta-amyloid protein probe hybridized to chromosome 9 in 3 Alzheimer disease individuals. Prog Clin Biol Res (1989) 0.75
Use of psychotropics in the world. Int Pharmacopsychiatry (1978) 0.75
Transcultural aspects of psychopharmacology. Curr Psychiatr Ther (1977) 0.75